- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biosimilars Immunology Roundup for July 2023—Podcast Edition
On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.
On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.
Show Notes
First Round of Adalimumab Biosimilar Launches in July
Celltrion Launches Yuflyma on the US Market
US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market
Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending?
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price
Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches
Multiple Infliximab Biosimilar Switches Were Safe, Effective
Adalimumab Biosimilar Improved Symptoms for up to 48 Weeks in Ankylosing Spondylitis
Biosimilar, Innovator Romiplostim Comparably Safe and Effective
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
